Audentes Therapeutics, Inc.

From Verify.Wiki
Jump to: navigation, search
Audentes Therapeutics, Inc.
Type Public
Industry Biotechnology
Founded 2012
Headquarters San Francisco, CA, United States
Key people Matthew R. Patterson (CEO), Suyash Prasad (Chief Medical Officer), John T. Gray [1]
Investors 5AM Ventures, Cormorant Asset Management, Deerfield, Foresite Capital, OrbiMed, RA Capital Management, Redmile Group, Rock Springs, Capital, Sofinnova Ventures, T. Rowe Price, Venrock, Versant Ventures [2]
Number of employees 76 [3]

Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects in the United States.
They follow that the gene therapy has powerful potential to treat these diseases through delivery of a functional copyof the affected gene to cells, resulting in production of the normal protein. [4]


The products include :

  • AT132 for the treatment of X-Linked Myotubular Myopathy
  • XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome
  • Crigler-Najjar, AT982 for the treatment of Pompe disease
  • AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia
  • CASQ2-CPVT. We plan to submit Investigational New Drug applications
  • INDs, or Clinical Trial Authorisations, or CTAs, for AT982 in the third quarter of 2016

They maintain full global rights to all of our product candidates. [5]


None Reported

Top 5 Recent Tweets

June 20, 2022_timos_Global Gene Therapy Market Research Report 2022-2031 Featuring Major Players - Novartis AG; Bluebird bio, Inc.; Spa…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history